A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

This study is looking for young people aged 9 to 17 years old who have Hidradenitis Suppurativa (HS). To be considered, you must have been diagnosed with HS for at least six months and have moderate to severe HS with at least five inflamed bumps (abscesses or painful lumps). Your HS should affect at least two different body areas, with at least one area being moderately or severely affected (known as Hurley Stage II or III). You also need to weigh at least 30 kilograms (about 4 stone 10 pounds) and have tried a course of antibiotics for your HS that didn't work well enough.

There are also some reasons why you might not be able to join. For example, if you have more than 20 draining tunnels from your HS, or if you've already tried certain biologic medicines (like brodalumab, ixekizumab, or secukinumab) for HS and they didn't help at all. You also can't join if you've been in this study before or have taken Bimekizumab previously. Other reasons include a history of certain bowel conditions (like Inflammatory Bowel Disease), active or untreated tuberculosis, or ongoing serious infections.

If you decide to take part in this study, you will receive doses of Bimekizumab, likely given as an injection under the skin. You will have regular visits to the clinic where the study team will monitor your health, assess your HS, and check for any side effects. This will involve physical examinations, blood tests, and potentially other procedures to see how the medicine is working and how you are feeling. The study will involve a number of visits over a period that isn't fully detailed here, but will be explained to you by the study team. You'll need to follow specific instructions about other medicines you might be taking. The study team will provide all the necessary medication and care related to the trial.